EBS

Emergent BioSolutions (EBS)

About Emergent BioSolutions (EBS)

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Details

Daily high
$12.63
Daily low
$12.08
Price at open
$12.25
52 Week High
$13.41
52 Week Low
$4.02
Market cap
640.2M
Dividend yield
0.00%
Volume
671,040
Avg. volume
849,231
P/E ratio
9.42

Emergent BioSolutions News

Details

Daily high
$12.63
Daily low
$12.08
Price at open
$12.25
52 Week High
$13.41
52 Week Low
$4.02
Market cap
640.2M
Dividend yield
0.00%
Volume
671,040
Avg. volume
849,231
P/E ratio
9.42